AbbVie Shares Drop 2.36% with 12.98 Billion Volume Ranking 52nd in Market Activity

AbbVie (ABBV) shares fell 2.36% on June 27, 2025, with a trading volume of 12.98 billion, ranking 52nd in the day's market activity.

AbbVie is accelerating its oncology development efforts, focusing on lung, gastrointestinal, and ovarian cancers following the 2025 ASCO Annual Meeting. The company is prioritizing antibody-drug conjugates (ADCs) and expanding late-stage studies. Pedro Valencia, VP of asset strategy leadership in oncology at AbbVie, highlighted the company's commitment to rapidly advancing its ADC pipeline, aiming to replace chemotherapy in various settings.

In non-small cell lung cancer (NSCLC), AbbVie is advancing telisotuzumab vedotin (teliso-v) into late-stage studies for both EGFR-mutant and EGFR wild-type settings. The company plans to evaluate teliso-v as monotherapy and in combination with osimertinib for EGFR-mutant NSCLC, and with pembrolizumab for EGFR wild-type NSCLC. These studies are expected to begin by the end of 2025.

In small cell lung cancer, ABBV-400 (also referred to as 706) will move into late-stage, frontline settings. AbbVie is preparing to explore combinations with anti-PD-(L)1 therapies to elevate the standard of care. In gastrointestinal tumors, particularly colorectal and pancreatic cancers, additional data on teliso-v will be shared this year, including the initiation and advancement of registrational studies.

For ovarian cancer, AbbVie is focused on rapidly advancing elahere (mirvetuximab soravtansine) into new treatment settings. This includes a second-line study for platinum-sensitive ovarian cancer and a frontline trial in the HRP population in combination with bevacizumab, both expected to begin by year-end. The company is also pushing forward with next-generation FRα-targeted ADCs designed to work across a broader range of tumor types and varying levels of FRα expression.